[Pharmacokinetic and clinical studies of ceftizoxime in the perinatal period. The Chemotherapy Research Group for Mothers and Children].
Pharmacokinetic and clinical studies of ceftizoxime (CZX) in the perinatal period gave the following results: 1. Peak concentrations of CZX in the maternal serum, umbilical cord serum and amniotic fluid in mothers after one intravenous injection of 1 g were, respectively, 70.2 micrograms/ml at 0 hour; 15.7 micrograms/ml at 0.5 hour; and 10-30 micrograms/ml at 3-6 hours. Concentrations of CZX in the neonatal serum were 0.87-13.5 micrograms/ml during 6-14 hours after parturition. The mean concentration of CZX in the milk in 1-8 hours after injection was less than 0.32-0.52 microgram/ml. 2. Good or excellent clinical efficacy was obtained in 28 of the 29 patients with perinatal infections, with an efficacy rate of 96.6%. Prophylactic effectiveness was obtained in 14 of the 15 patients, with an efficacy rate of 93.3%. 3. No side effects were observed in 44 cases. GOT and GPT values increased slightly in 1 patient. No abnormal values in total serum bilirubin or other parameters were found in any neonates after parturition. 4. The above results suggest that CZX is safe and effective for the treatment and prophylaxis of infection in the perinatal period.
D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control; D015296:Ceftizoxime / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D008431:Maternal-Fetal Exchange; D015337:Multicenter Studies as Topic; D049590:Postpartum Period / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism; D011645:Puerperal Infection / Q000188:drug therapy* / Q000378:metabolism; D011704:Pyelonephritis / Q000188:drug therapy* / Q000378:metabolism; D014591:Uterine Diseases / Q000188:drug therapy* / Q000378:metabolism
D015296:Ceftizoxime